Finding a cure for inflammatory bowel disease (IBD) would mean reducing treatment waste, according to Ashwin N.

Microbiotica unveils multiple mechanisms by which MB310, in clinical development for the treatment of ulcerative colitis, protects the intestinal barrierData presented at Digestive Disease Week in San ...

Recent years have seen significant advancements in UC treatment, offering renewed hope for patients seeking effective and ...

Stroke and coronary artery disease were the primary causes linked to the deaths of all participants with autoimmune disease, ...

Hunter Renfrow is mounting an NFL comeback after spending the 2024 season out of the league battling ulcerative colitis. Here ...

Johnson & Johnson (NYSE: JNJ) today announced new data from the TREMFYA® (guselkumab) Phase 3 QUASAR long-term extension (LTE) study in adults with moderately-to-severely active ulcerative colitis (UC ...

In 2021, Sly, biochemistry professor Harry Brumer, and a group of other researchers at the UBC developed GlycoCage, a ...

Johnson & Johnson announces new data from Tremfya phase 3 QUASAR LTE study in adults with moderately-to-severely active ulcerative colitis: San Diego, California Tuesday, May 6, 2 ...

DelveInsight’s “Ulcerative Colitis Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth ...